CA2121041A1 - Composite antibodies of human subgroup iv light chain capable of binding to tag-72 - Google Patents

Composite antibodies of human subgroup iv light chain capable of binding to tag-72

Info

Publication number
CA2121041A1
CA2121041A1 CA002121041A CA2121041A CA2121041A1 CA 2121041 A1 CA2121041 A1 CA 2121041A1 CA 002121041 A CA002121041 A CA 002121041A CA 2121041 A CA2121041 A CA 2121041A CA 2121041 A1 CA2121041 A1 CA 2121041A1
Authority
CA
Canada
Prior art keywords
tag
antibodies
binding
composite
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002121041A
Other languages
French (fr)
Other versions
CA2121041C (en
Inventor
Peter S. Mezes
Ruth A. Richard
Kim S. Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dow Chemical Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP4502011A priority Critical patent/JPH07501922A/en
Priority to PCT/AU1991/000583 priority patent/WO1993012231A1/en
Priority to CA002121041A priority patent/CA2121041C/en
Priority to EP92901213A priority patent/EP0618969B1/en
Priority to AU90582/91A priority patent/AU9058291A/en
Application filed by Individual filed Critical Individual
Priority claimed from PCT/AU1991/000583 external-priority patent/WO1993012231A1/en
Priority claimed from SG1996004881A external-priority patent/SG55075A1/en
Publication of CA2121041A1 publication Critical patent/CA2121041A1/en
Application granted granted Critical
Publication of CA2121041C publication Critical patent/CA2121041C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A61K51/1063—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from stomach or intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/1087—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin the immunoglobulin comprises domains from different animal species, e.g. chimeric immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

This invention concerns a subset of composite Hum4 V L, V H .alpha.TAG
antibody with high affinities to a high molecular weight; tumor-associated sislylated glycoprotein antigen (TAG-72) of human origin. These antibodies have variable regions with (1) V L segments derived from the human subgroup IV germline gene and (2) a V
H segment which is capable of combining with the V L to form a three dimensional structure having the ability to bind TAG-72. in vivo methods of treatment and diagnostic assay using these composite antibodies is also disclosed.
CA002121041A 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72 Expired - Fee Related CA2121041C (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
PCT/AU1991/000583 WO1993012231A1 (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72
CA002121041A CA2121041C (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72
EP92901213A EP0618969B1 (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72
AU90582/91A AU9058291A (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup IV light chain capable of binding to tag-72
JP4502011A JPH07501922A (en) 1991-12-13 1991-12-13 Human subgroup IV light chain conjugate antibody that can bind to TAG-72

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/AU1991/000583 WO1993012231A1 (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72
CA002121041A CA2121041C (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72
SG1996004881A SG55075A1 (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72

Publications (2)

Publication Number Publication Date
CA2121041A1 true CA2121041A1 (en) 1993-06-24
CA2121041C CA2121041C (en) 2004-08-10

Family

ID=25677179

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002121041A Expired - Fee Related CA2121041C (en) 1991-12-13 1991-12-13 Composite antibodies of human subgroup iv light chain capable of binding to tag-72

Country Status (3)

Country Link
JP (1) JPH07501922A (en)
AU (1) AU9058291A (en)
CA (1) CA2121041C (en)

Also Published As

Publication number Publication date
JPH07501922A (en) 1995-03-02
AU9058291A (en) 1993-07-19
CA2121041C (en) 2004-08-10

Similar Documents

Publication Publication Date Title
EP1878746A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
CA2000913A1 (en) Family of high affinity antibodies for cancer treatment
NZ529571A (en) Human antibodies that bind human IL-12 and methods for producing
CA2060544A1 (en) Recombinant antibodies specific for a growth factor receptor
WO1997046589A3 (en) Humanized antibodies that bind to the same antigen as bound by antibody nr-lu-13, and their use in pretargeting methods
CA2006865A1 (en) Humanized immunoglobulins and their production and use
CA2210751A1 (en) Anti-cd6 monoclonal antibodies and their uses
KR910001057A (en) Bispecific and oligospecific monovalent and oligovalent receptors. The preparation method thereof and its use
EP1808155A3 (en) Antibody-serum protein hybrids
CA2091769A1 (en) Framework mutated antibodies and their preparation
RU94045919A (en) Antibodies, cells, polypeptide, dna, vectors, method of polypeptide preparing, method of antibody preparing, pharmaceutical composition
UA27763C2 (en) RECOMBINANT DNA MOLECULE ENCODING ICAM-3 ADHESION MOLECULE, ICAM-3 ADHESION MOLECULE, ANTIBODY ABLE TO BIND SUCH MATUCHATUS
GR3020610T3 (en) Monoclonal antibodies against tumor associated antigen, their preparation and use
DE69414870D1 (en) ANTIBODY WITH CHANGED TARGET DIRECTION
EP0672253A4 (en) Carcinoma associated antigen (sk1) monoclonal antibodies against sk1, methods of producing these antibodies and use therfor.
EP1176201A3 (en) Platelet-specific chimeric immunoglobulin
ES2127531T3 (en) MEDICATION FOR PROLONGED IMMUNOSUPPRESSION AND ELIMINATION OF TUMOR CELLS.
ES2149159T3 (en) FUSION PROTEINS CONTAINED IN MONOCLONAL ANTIBODIES, LINKER- AND BETA-GLUCURONIDASE, INTENDED FOR THE ACTIVATION OF DRUGS, THEIR PREPARATION AND USE.
CA2217776A1 (en) Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
CA2126182A1 (en) Humanized antibodies reactive with gpiib/iiia
CA2121041A1 (en) Composite antibodies of human subgroup iv light chain capable of binding to tag-72
AU4264097A (en) Mage-10 encoding cdna, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
CA2088889A1 (en) Specific antibodies against activated platelets, the preparation thereof and the use thereof in diagnosis and therapy
CA2038030A1 (en) Synthetic peptides which contain sequences from factor viia, and the use thereof
AU2169797A (en) Improved production of antibodies through the use of antigen antibody complexes

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed